MAGE-1, human recombinant protein
Melanoma-associated antigen 1, MAGE-1 antigen, Antigen MZ2-E, Cancer/testis antigen 1,1, CT1,1, MAGE
|Calculated MW||38 kDa|
|Other Names||Melanoma-associated antigen 1, MAGE-1 antigen, Antigen MZ2-E, Cancer/testis antigen 1, 1, CT1, 1, MAGEA1, MAGE1, MAGE1A, MGC9326,|
|Storage||-20°C; Sterile filtered solution. 50 ul (100 mg/ml) purified human MAGE-1 in 50 mM Tris-Acetate, pH 7.5, 1 mM EDTA and 20% glycerol.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Human malignant neoplasms carry rejection antigens that are recognized by the patients autologous, tumor directed and specific, cytolytic, CD8+T lymphocyte clones (CTL). An important group of antigens is coded by the MAGE family of genes. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.